Trial Profile
Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 May 2019
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Apr 2018 New trial record